PT - JOURNAL ARTICLE AU - A Metcalfe-Roach AU - AC Yu AU - E Golz AU - K Sundvick AU - MS Cirstea AU - D Kliger AU - LH Foulger AU - M Mackenzie AU - BB Finlay AU - S Appel-Cresswell TI - MIND diet associated with later onset of Parkinson’s disease AID - 10.1101/2020.07.13.20151977 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.13.20151977 4099 - http://medrxiv.org/content/early/2020/09/22/2020.07.13.20151977.short 4100 - http://medrxiv.org/content/early/2020/09/22/2020.07.13.20151977.full AB - Background The MIND diet has been linked with prevention of Alzheimer’s disease and cognitive decline but has not been fully assessed in the context of Parkinson’s disease (PD).Objective To determine whether MIND diet adherence is associated with the age of Parkinson’s disease onset in a manner superior to that of the Mediterranean diet.Methods Food Frequency Questionnaires from 167 participants with PD and 119 controls were scored for MIND and two versions of Mediterranean diet adherence. Scores were compared between sex and disease subgroups, and PD diet adherence was correlated with age of onset using univariate and multivariate linear models.Results The female subgroup adhered more closely to the MIND diet than the males, and diet scores were not modified by disease status. Later age of onset correlated most strongly with MIND diet adherence in the female subgroup, corresponding to differences of up to 17.4 years (p<0.001) between low and high dietary tertiles. Greek Mediterranean adherence was also significantly associated with later PD onset across all models (p=0.05-0.03). Conversely, only Greek Mediterranean adherence remained correlated with later onset across all models in men, with differences of up to 8.4 years (p=0.002).Conclusions This cross-sectional study finds a strong correlation of age of onset of PD with dietary habits, suggesting that nutritional strategies may be an effective tool to delay PD onset. Further studies may help to elucidate potential nutrition-related sex-specific pathophysiological mechanisms and differential prevalence rates in PD.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/A - Observational studyFunding StatementThis work was supported by grants from the Canadian Institutes of Health Research, the Pacific Parkinson's Research Institute, and Parkinson Canada / Parkinson Society British Columbia. AMR and MSC are supported by CIHR CGSM and Vanier Scholarships respectively. BBF is the UBC Peter Wall Distinguished Professor. Dr Appel-Cresswell is supported by the Marg Meikle Professorship for research in Parkinson's disease.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the UBC Clinical Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo patient data is being released with this manuscript.